Research map: Anti-TNF therapy in autoimmune hepatitis: We should move faster

Back to the article

Papers in this map

  1. Infliximab as a rescue treatment in difficult-to-treat autoimmune hepatitis · Christina Weiler‐Normann · 2012 · 237 citations · Cited by this paper
  2. Quantitative Bias Analysis of Unmeasured Confounding Refines Interpretation of Longitudinal Associations Between Cardiometabolic Risk Factors and Liver Stiffness in MASLD · 2026 · Related
  3. Patient selection based on treatment duration and liver biochemistry increases success rates after treatment withdrawal in autoimmune hepatitis · Johannes Hartl · 2014 · 109 citations · Cited by this paper
  4. Updates in clinical science: Alcohol-related hepatitis · 2026 · Related
  5. Treatment response and clinical event-free survival in autoimmune hepatitis: A Canadian multicentre cohort study · Christina Plagiannakos · 2024 · 44 citations · Cited by this paper
  6. Low-dose bevacizumab plus atezolizumab enhances transarterial chemoembolization in HCC via correcting vascular-immune niche dysfunction · 2026 · Related
  7. Efficacy and safety of infliximab in patients with autoimmune hepatitis · Cumali Efe · 2024 · 28 citations · Cited by this paper
  8. OSM-STAT3 signaling facilitates Long-term expansion of Pediatric Hepatic Organoids · 2026 · Related
  9. Integrative omics and phase IIa clinical trial identify TNF as key node in autoimmune hepatitis · Yang Xu · 2026 · 8 citations · Cited by this paper
  10. JHEP at a glance (August 2026) · 2026 · Related
  11. Moving Too Fast? A Meta-Analysis Calls for Caution on TNF Inhibitors as First-Line Therapy for Autoimmune Hepatitis · Wenhui Mo · 2026 · 1 citation · Cited by this paper
  12. Before repurposing Fusobacterium nucleatum in alcohol-associated liver disease: it is a rare, non-resident organism in the human alcoholic gut · 2026 · Related
  13. Beyond steroid-dependent care: Can TNF blockade evolve into a precision therapy for autoimmune hepatitis? · Xinghuan Fu · 2026 · 1 citation · Cited by this paper
  14. Declining but persistent hepatocellular cancer risk beyond 10 years of entecavir or tenofovir in chronic hepatitis B: Results of the PAGE-B cohort · 2026 · Related
  15. Non-selective β-blockers reduce bacterial translocation by restoring gut barrier function during experimental cirrhosis · 2026 · Related
  16. Metabolic dysfunction profiles identify heterogeneous hepatocellular carcinoma risk in MASLD-associated advanced fibrosis · 2026 · Related

Source: OpenAlex (CC0)